drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB11575 | DB12941 | 1,676 | 466 | [
"DDInter841",
"DDInter481"
] | Grazoprevir | Darolutamide | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Major | 2 | [
[
[
1676,
25,
466
]
],
[
[
1676,
64,
1374
],
[
1374,
23,
466
]
],
[
[
1676,
63,
600
],
[
600,
23,
466
]
],
[
[
1676,
24,
351
],
[
351,
... | [
[
[
"Grazoprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Grazoprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
... | Grazoprevir may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Grazoprevir may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may ... |
DB00015 | DB00963 | 582 | 1,263 | [
"DDInter1585",
"DDInter241"
] | Reteplase | Bromfenac | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Moderate | 1 | [
[
[
582,
24,
1263
]
],
[
[
582,
24,
935
],
[
935,
40,
1263
]
],
[
[
582,
24,
1512
],
[
1512,
24,
1263
]
],
[
[
582,
24,
578
],
[
578,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could ex... |
DB00364 | DB12035 | 417 | 943 | [
"DDInter1717",
"DDInter1641"
] | Sucralfate | Sarecycline | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
417,
24,
943
]
],
[
[
417,
24,
170
],
[
170,
24,
943
]
],
[
[
417,
24,
170
],
[
170,
24,
850
],
[
850,
24,
943
]
],
[
[
417,
24,... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Si... |
DB00902 | DB06282 | 104 | 516 | [
"DDInter1168",
"DDInter1053"
] | Methdilazine | Levocetirizine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
104,
24,
516
]
],
[
[
104,
23,
771
],
[
771,
62,
516
]
],
[
[
104,
24,
1074
],
[
1074,
63,
516
]
],
[
[
104,
63,
701
],
[
701,
2... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Methdilazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],... | Methdilazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-12... |
DB00563 | DB11943 | 663 | 255 | [
"DDInter1174",
"DDInter495"
] | Methotrexate | Delafloxacin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
663,
24,
255
]
],
[
[
663,
24,
372
],
[
372,
23,
255
]
],
[
[
663,
63,
377
],
[
377,
23,
255
]
],
[
[
663,
23,
328
],
[
328,
23,... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and M... |
DB00705 | DB01259 | 441 | 392 | [
"DDInter496",
"DDInter1024"
] | Delavirdine | Lapatinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
441,
25,
392
]
],
[
[
441,
6,
8374
],
[
8374,
45,
392
]
],
[
[
441,
21,
28674
],
[
28674,
60,
392
]
],
[
[
441,
25,
1135
],
[
1135,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lapati... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Delavirdine (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Delavirdine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol m... |
DB00470 | DB00584 | 530 | 610 | [
"DDInter601",
"DDInter638"
] | Dronabinol | Enalapril | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
530,
24,
610
]
],
[
[
530,
24,
743
],
[
743,
1,
610
]
],
[
[
530,
24,
954
],
[
954,
40,
610
]
],
[
[
530,
6,
8374
],
[
8374,
45,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril (Compound)
Dron... |
DB00862 | DB08871 | 1,005 | 36 | [
"DDInter1918",
"DDInter666"
] | Vardenafil | Eribulin | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1005,
24,
36
]
],
[
[
1005,
63,
1424
],
[
1424,
24,
36
]
],
[
[
1005,
24,
820
],
[
820,
24,
36
]
],
[
[
1005,
25,
609
],
[
609,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine m... |
DB01083 | DB01261 | 1,142 | 170 | [
"DDInter1348",
"DDInter1679"
] | Orlistat | Sitagliptin | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1142,
24,
170
]
],
[
[
1142,
5,
11640
],
[
11640,
44,
170
]
],
[
[
1142,
6,
8374
],
[
8374,
45,
170
]
],
[
[
1142,
6,
5599
],
[
5599,
... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Orlistat",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u... | Orlistat (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Orlistat (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Orlistat (Compound) binds PLA2G4A (Gene) and PLA2G4A (Gene) is downregulated by Sitaglipt... |
DB00022 | DB04845 | 268 | 309 | [
"DDInter1408",
"DDInter1001"
] | Peginterferon alfa-2b | Ixabepilone | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
268,
24,
309
]
],
[
[
268,
25,
139
],
[
139,
24,
309
]
],
[
[
268,
24,
1434
],
[
1434,
63,
309
]
],
[
[
268,
24,
1487
],
[
1487,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
... | Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole ... |
DB00331 | DB11730 | 1,645 | 351 | [
"DDInter1164",
"DDInter1588"
] | Metformin | Ribociclib | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1645,
24,
351
]
],
[
[
1645,
24,
222
],
[
222,
23,
351
]
],
[
[
1645,
24,
1654
],
[
1654,
63,
351
]
],
[
[
1645,
25,
306
],
[
306,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapac... |
DB00816 | DB01175 | 1,674 | 318 | [
"DDInter1346",
"DDInter672"
] | Orciprenaline | Escitalopram | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
1674,
25,
318
]
],
[
[
1674,
64,
1230
],
[
1230,
1,
318
]
],
[
[
1674,
7,
8587
],
[
8587,
46,
318
]
],
[
[
1674,
21,
28750
],
[
28750,... | [
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Orciprenaline may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Orciprenaline (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Escitalopram (Compound)
Orciprenaline (Compound) causes Abdominal discomfort (Side Effe... |
DB00443 | DB00790 | 251 | 664 | [
"DDInter195",
"DDInter1431"
] | Betamethasone | Perindopril | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Moderate | 1 | [
[
[
251,
24,
664
]
],
[
[
251,
24,
1638
],
[
1638,
1,
664
]
],
[
[
251,
24,
954
],
[
954,
40,
664
]
],
[
[
251,
6,
4973
],
[
4973,
4... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (... |
DB00884 | DB11126 | 1,008 | 900 | [
"DDInter1604",
"DDInter276"
] | Risedronic acid | Calcium gluconate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1008,
24,
900
]
],
[
[
1008,
40,
1199
],
[
1199,
24,
900
]
],
[
[
1008,
40,
1199
],
[
1199,
40,
1485
],
[
1485,
24,
900
]
],
[
[
1008,... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Risedronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} ... | Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid ma... |
DB00344 | DB00366 | 1,302 | 1,594 | [
"DDInter1543",
"DDInter600"
] | Protriptyline | Doxylamine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
1302,
24,
1594
]
],
[
[
1302,
25,
11
],
[
11,
1,
1594
]
],
[
[
1302,
24,
662
],
[
662,
63,
1594
]
],
[
[
1302,
24,
888
],
[
888,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Tore... | Protriptyline may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Doxylamine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could ex... |
DB00375 | DB00759 | 1,037 | 1,620 | [
"DDInter433",
"DDInter1783"
] | Colestipol | Tetracycline | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Minor | 0 | [
[
[
1037,
23,
1620
]
],
[
[
1037,
23,
1572
],
[
1572,
40,
1620
]
],
[
[
1037,
62,
964
],
[
964,
40,
1620
]
],
[
[
1037,
23,
126
],
[
126,
... | [
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
]
],
[
[
"Colestipol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
... | Colestipol may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Colestipol may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Tetracycline (... |
DB00390 | DB01073 | 1,252 | 1,488 | [
"DDInter554",
"DDInter745"
] | Digoxin | Fludarabine | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1252,
24,
1488
]
],
[
[
1252,
21,
28714
],
[
28714,
60,
1488
]
],
[
[
1252,
24,
1487
],
[
1487,
63,
1488
]
],
[
[
1252,
63,
329
],
[
3... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {... | Digoxin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fludarabine (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00067 | DB06589 | 317 | 1,250 | [
"DDInter1921",
"DDInter1400"
] | Vasopressin | Pazopanib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
317,
24,
1250
]
],
[
[
317,
23,
112
],
[
112,
23,
1250
]
],
[
[
317,
24,
1151
],
[
1151,
24,
1250
]
],
[
[
317,
24,
913
],
[
913,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suni... |
DB00741 | DB00951 | 167 | 1,072 | [
"DDInter885",
"DDInter986"
] | Hydrocortisone | Isoniazid | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Minor | 0 | [
[
[
167,
23,
1072
]
],
[
[
167,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
167,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
167,
1,
1486
],
[
1486,
... | [
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Hydrocortisone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a minor int... |
DB00902 | DB01114 | 104 | 272 | [
"DDInter1168",
"DDInter362"
] | Methdilazine | Chlorpheniramine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
104,
24,
272
]
],
[
[
104,
24,
358
],
[
358,
63,
272
]
],
[
[
104,
63,
128
],
[
128,
24,
272
]
],
[
[
104,
6,
10104
],
[
10104,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrom... |
DB00398 | DB00734 | 79 | 1,664 | [
"DDInter1702",
"DDInter1605"
] | Sorafenib | Risperidone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
79,
24,
1664
]
],
[
[
79,
25,
924
],
[
924,
40,
1664
]
],
[
[
79,
24,
519
],
[
519,
40,
1664
]
],
[
[
79,
6,
4973
],
[
4973,
45,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidon... | Sorafenib may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Sorafenib... |
DB00945 | DB10344 | 1,479 | 992 | [
"DDInter20",
"DDInter818"
] | Acetylsalicylic acid | Ginger | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1479,
24,
992
]
],
[
[
1479,
63,
1578
],
[
1578,
24,
992
]
],
[
[
1479,
25,
1421
],
[
1421,
63,
992
]
],
[
[
1479,
25,
500
],
[
500,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Betrixaban and Betrixa... |
DB00951 | DB01218 | 1,072 | 1,493 | [
"DDInter986",
"DDInter852"
] | Isoniazid | Halofantrine | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1072,
25,
1493
]
],
[
[
1072,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
1072,
21,
28709
],
[
28709,
60,
1493
]
],
[
[
1072,
63,
112
],
[
11... | [
[
[
"Isoniazid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Isoniazid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Halofan... | Isoniazid (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Isoniazid (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Halofantrine (Compound)
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00204 | DB12267 | 228 | 1,476 | [
"DDInter580",
"DDInter233"
] | Dofetilide | Brigatinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
228,
24,
1476
]
],
[
[
228,
24,
629
],
[
629,
24,
1476
]
],
[
[
228,
25,
918
],
[
918,
24,
1476
]
],
[
[
228,
25,
982
],
[
982,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dofetilide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may caus... |
DB00242 | DB00363 | 1,064 | 695 | [
"DDInter392",
"DDInter419"
] | Cladribine | Clozapine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
1064,
25,
695
]
],
[
[
1064,
18,
17366
],
[
17366,
57,
695
]
],
[
[
1064,
24,
303
],
[
303,
63,
695
]
],
[
[
1064,
25,
1001
],
[
1001,... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Cladribine",
"{u} (Compound) downregulates {v} (Gene)",
"C2CD5"
],
[
"C2CD5",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Cladribine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Clozapine (Compound)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate disease... |
DB05015 | DB08896 | 1,077 | 292 | [
"DDInter174",
"DDInter1576"
] | Belinostat | Regorafenib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1077,
24,
292
]
],
[
[
1077,
63,
79
],
[
79,
1,
292
]
],
[
[
1077,
24,
327
],
[
327,
63,
292
]
],
[
[
1077,
63,
1560
],
[
1560,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could ... |
DB00549 | DB01100 | 522 | 1,568 | [
"DDInter1955",
"DDInter1470"
] | Zafirlukast | Pimozide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
522,
25,
1568
]
],
[
[
522,
6,
6365
],
[
6365,
45,
1568
]
],
[
[
522,
21,
28921
],
[
28921,
60,
1568
]
],
[
[
522,
24,
112
],
[
112,
... | [
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Pimozid... | Zafirlukast (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Pimozide (Compound)
Zafirlukast (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Pimozide (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Me... |
DB08930 | DB12130 | 1,459 | 1,017 | [
"DDInter582",
"DDInter1094"
] | Dolutegravir | Lorlatinib | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Minor | 0 | [
[
[
1459,
23,
1017
]
],
[
[
1459,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
1459,
62,
1213
],
[
1213,
24,
1017
]
],
[
[
1459,
23,
98
],
[
98,
... | [
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Dasatinib and Dasatinib... |
DB04865 | DB09498 | 4 | 810 | [
"DDInter1335",
"DDInter1715"
] | Omacetaxine mepesuccinate | Strontium chloride Sr-89 | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
4,
24,
810
]
],
[
[
4,
63,
552
],
[
552,
24,
810
]
],
[
[
4,
24,
689
],
[
689,
63,
810
]
],
[
[
4,
64,
273
],
[
273,
24,
8... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate di... |
DB01259 | DB11113 | 392 | 657 | [
"DDInter1024",
"DDInter307"
] | Lapatinib | Castor oil | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
392,
24,
657
]
],
[
[
392,
24,
1079
],
[
1079,
24,
657
]
],
[
[
392,
24,
927
],
[
927,
63,
657
]
],
[
[
392,
25,
540
],
[
540,
2... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encoraf... |
DB00087 | DB15091 | 599 | 676 | [
"DDInter41",
"DDInter1901"
] | Alemtuzumab | Upadacitinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
599,
25,
676
]
],
[
[
599,
24,
1430
],
[
1430,
24,
676
]
],
[
[
599,
63,
1184
],
[
1184,
25,
676
]
],
[
[
599,
24,
503
],
[
503,
... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and ... |
DB00030 | DB00220 | 1,685 | 798 | [
"DDInter934",
"DDInter1276"
] | Insulin human | Nelfinavir | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Moderate | 1 | [
[
[
1685,
24,
798
]
],
[
[
1685,
24,
215
],
[
215,
40,
798
]
],
[
[
1685,
24,
1327
],
[
1327,
1,
798
]
],
[
[
1685,
24,
222
],
[
222,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir (Compound) resembles Nelfinavir (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Nelfinavir (Compou... |
DB00726 | DB01218 | 1,164 | 1,493 | [
"DDInter1876",
"DDInter852"
] | Trimipramine | Halofantrine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1164,
25,
1493
]
],
[
[
1164,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
1164,
21,
28809
],
[
28809,
60,
1493
]
],
[
[
1164,
23,
112
],
[
... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Trimipramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Trimipramine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Halofantrine (Compound)
Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB00222 | DB08882 | 245 | 1,281 | [
"DDInter825",
"DDInter1070"
] | Glimepiride | Linagliptin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
245,
24,
1281
]
],
[
[
245,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
245,
5,
11640
],
[
11640,
44,
1281
]
],
[
[
245,
21,
30552
],
[
30552... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Linagliptin (Compound)
Glimepiride (Comp... |
DB00404 | DB01254 | 523 | 1,213 | [
"DDInter54",
"DDInter484"
] | Alprazolam | Dasatinib | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
523,
24,
1213
]
],
[
[
523,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
523,
7,
3361
],
[
3361,
46,
1213
]
],
[
[
523,
18,
6317
],
[
6317,
... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alprazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Alprazolam (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Dasatinib (Compound)
Alprazolam (Compound) downregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Dasatinib (Compound)
Alprazolam (Com... |
DB00619 | DB00704 | 1,419 | 267 | [
"DDInter909",
"DDInter1263"
] | Imatinib | Naltrexone | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1419,
24,
267
]
],
[
[
1419,
64,
828
],
[
828,
25,
267
]
],
[
[
1419,
63,
475
],
[
475,
25,
267
]
],
[
[
1419,
6,
4973
],
[
4973,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
... | Imatinib may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatenin... |
DB10795 | DB12001 | 221 | 564 | [
"DDInter1486",
"DDInter7"
] | Poliovirus type 1 antigen (formaldehyde inactivated) | Abemaciclib | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
221,
24,
564
]
],
[
[
221,
63,
58
],
[
58,
24,
564
]
],
[
[
221,
24,
351
],
[
351,
24,
564
]
],
[
[
221,
24,
1476
],
[
1476,
63,... | [
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction th... | Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a modera... |
DB08895 | DB11767 | 976 | 1,583 | [
"DDInter1825",
"DDInter1643"
] | Tofacitinib | Sarilumab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
976,
25,
1583
]
],
[
[
976,
62,
1461
],
[
1461,
23,
1583
]
],
[
[
976,
23,
1114
],
[
1114,
23,
1583
]
],
[
[
976,
24,
1186
],
[
1186,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfat... |
DB00108 | DB01041 | 1,066 | 770 | [
"DDInter1268",
"DDInter1789"
] | Natalizumab | Thalidomide | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1066,
25,
770
]
],
[
[
1066,
25,
1668
],
[
1668,
1,
770
]
],
[
[
1066,
25,
4
],
[
4,
63,
770
]
],
[
[
1066,
25,
453
],
[
453,
24... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
... | Natalizumab may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction tha... |
DB00679 | DB14568 | 684 | 982 | [
"DDInter1796",
"DDInter1000"
] | Thioridazine | Ivosidenib | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
684,
25,
982
]
],
[
[
684,
23,
112
],
[
112,
23,
982
]
],
[
[
684,
24,
543
],
[
543,
24,
982
]
],
[
[
684,
25,
1383
],
[
1383,
2... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Thioridazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Thioridazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and ... |
DB04845 | DB15091 | 309 | 676 | [
"DDInter1001",
"DDInter1901"
] | Ixabepilone | Upadacitinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
309,
25,
676
]
],
[
[
309,
63,
1461
],
[
1461,
23,
676
]
],
[
[
309,
24,
1430
],
[
1430,
24,
676
]
],
[
[
309,
63,
1249
],
[
1249,
... | [
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB00771 | DB01235 | 262 | 1,191 | [
"DDInter397",
"DDInter1054"
] | Clidinium | Levodopa | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
262,
24,
1191
]
],
[
[
262,
24,
1264
],
[
1264,
23,
1191
]
],
[
[
262,
24,
1376
],
[
1376,
24,
1191
]
],
[
[
262,
24,
1511
],
[
1511,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Do... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Levodopa
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydrami... |
DB00584 | DB09268 | 610 | 1,662 | [
"DDInter638",
"DDInter1464"
] | Enalapril | Picosulfuric acid | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
610,
24,
1662
]
],
[
[
610,
1,
1603
],
[
1603,
24,
1662
]
],
[
[
610,
24,
708
],
[
708,
24,
1662
]
],
[
[
610,
63,
912
],
[
912,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
],
[
"Captopril",
"{u} may cause a mode... | Enalapril (Compound) resembles Captopril (Compound) and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction t... |
DB01097 | DB11767 | 1,377 | 1,583 | [
"DDInter1033",
"DDInter1643"
] | Leflunomide | Sarilumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
1377,
25,
1583
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
1583
]
],
[
[
1377,
23,
1114
],
[
1114,
23,
1583
]
],
[
[
1377,
64,
267
],
[
267... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfat... |
DB00224 | DB06603 | 215 | 39 | [
"DDInter917",
"DDInter1387"
] | Indinavir | Panobinostat | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
215,
25,
39
]
],
[
[
215,
25,
455
],
[
455,
24,
39
]
],
[
[
215,
25,
578
],
[
578,
63,
39
]
],
[
[
215,
24,
850
],
[
850,
63,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} m... | Indinavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Indinavir may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate inte... |
DB00959 | DB01001 | 1,486 | 688 | [
"DDInter1191",
"DDInter1632"
] | Methylprednisolone | Salbutamol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Minor | 0 | [
[
[
1486,
23,
688
]
],
[
[
1486,
62,
455
],
[
455,
24,
688
]
],
[
[
1486,
23,
1148
],
[
1148,
63,
688
]
],
[
[
1486,
5,
11649
],
[
11649,
... | [
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
... | Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoprenal... |
DB00108 | DB00860 | 1,066 | 891 | [
"DDInter1268",
"DDInter1513"
] | Natalizumab | Prednisolone | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Major | 2 | [
[
[
1066,
25,
891
]
],
[
[
1066,
25,
175
],
[
175,
40,
891
]
],
[
[
1066,
25,
167
],
[
167,
1,
891
]
],
[
[
1066,
23,
1114
],
[
1114,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Natalizumab may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisolone (Compound)
Natalizuma... |
DB00159 | DB01240 | 940 | 885 | [
"DDInter903",
"DDInter657"
] | Icosapent | Epoprostenol | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
940,
24,
885
]
],
[
[
940,
24,
1061
],
[
1061,
1,
885
]
],
[
[
940,
21,
28996
],
[
28996,
60,
885
]
],
[
[
940,
24,
1512
],
[
1512,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Icosapent (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Epoprostenol (Compound)
Icos... |
DB09381 | DB12130 | 192 | 1,017 | [
"DDInter678",
"DDInter1094"
] | Esterified estrogens | Lorlatinib | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
192,
24,
1017
]
],
[
[
192,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
192,
63,
590
],
[
590,
24,
1017
]
],
[
[
192,
24,
214
],
[
214,
... | [
[
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarot... | Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Ace... |
DB00647 | DB11113 | 675 | 657 | [
"DDInter528",
"DDInter307"
] | Dextropropoxyphene | Castor oil | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
675,
24,
657
]
],
[
[
675,
24,
927
],
[
927,
63,
657
]
],
[
[
675,
24,
1491
],
[
1491,
24,
657
]
],
[
[
675,
25,
985
],
[
985,
2... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib... | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mid... |
DB00618 | DB09401 | 1,572 | 928 | [
"DDInter498",
"DDInter988"
] | Demeclocycline | Isosorbide | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the... | Minor | 0 | [
[
[
1572,
23,
928
]
],
[
[
1572,
40,
964
],
[
964,
23,
928
]
],
[
[
1572,
1,
753
],
[
753,
40,
964
],
[
964,
23,
928
]
],
[
[
1572,
... | [
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isosorbide"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a... | Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Isosorbide
Demeclocycline (Compound) resembles Tigecycline (Compound) and Tigecycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor int... |
DB00563 | DB00827 | 663 | 646 | [
"DDInter1174",
"DDInter383"
] | Methotrexate | Cinoxacin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Moderate | 1 | [
[
[
663,
24,
646
]
],
[
[
663,
6,
10612
],
[
10612,
45,
646
]
],
[
[
663,
21,
28691
],
[
28691,
60,
646
]
],
[
[
663,
24,
77
],
[
77,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compou... | Methotrexate (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Cinoxacin (Compound)
Methotrexate (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Cinoxacin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin ... |
DB00197 | DB00741 | 1,324 | 167 | [
"DDInter1881",
"DDInter885"
] | Troglitazone | Hydrocortisone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1324,
24,
167
]
],
[
[
1324,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1324,
24,
870
],
[
870,
1,
167
]
],
[
[
1324,
24,
1561
],
[
1561,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resemble... |
DB01246 | DB01611 | 820 | 1,487 | [
"DDInter45",
"DDInter893"
] | Alimemazine | Hydroxychloroquine | A phenothiazine derivative that is used as an antipruritic. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
820,
25,
1487
]
],
[
[
820,
63,
1520
],
[
1520,
25,
1487
]
],
[
[
820,
21,
28741
],
[
28741,
60,
1487
]
],
[
[
820,
62,
1247
],
[
1247... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Alimemazine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Hydroxychloroquine (Com... |
DB00366 | DB01563 | 1,594 | 680 | [
"DDInter600",
"DDInter349"
] | Doxylamine | Chloral hydrate | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1594,
24,
680
]
],
[
[
1594,
35,
272
],
[
272,
24,
680
]
],
[
[
1594,
24,
1614
],
[
1614,
24,
680
]
],
[
[
1594,
24,
1609
],
[
1609,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ta... | Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Doxylamine may cause a moderate... |
DB00054 | DB06605 | 1,432 | 1,409 | [
"DDInter6",
"DDInter108"
] | Abciximab | Apixaban | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1432,
25,
1409
]
],
[
[
1432,
23,
539
],
[
539,
62,
1409
]
],
[
[
1432,
24,
109
],
[
109,
24,
1409
]
],
[
[
1432,
24,
41
],
[
41,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cau... |
DB06772 | DB15965 | 310 | 1,330 | [
"DDInter259",
"DDInter1270"
] | Cabazitaxel | Naxitamab | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
310,
24,
1330
]
],
[
[
310,
63,
14
],
[
14,
24,
1330
]
],
[
[
310,
24,
350
],
[
350,
24,
1330
]
],
[
[
310,
25,
375
],
[
375,
25... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and ... |
DB01114 | DB01148 | 272 | 1,128 | [
"DDInter362",
"DDInter738"
] | Chlorpheniramine | Flavoxate | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
272,
24,
1128
]
],
[
[
272,
40,
11268
],
[
11268,
40,
1128
]
],
[
[
272,
21,
28748
],
[
28748,
60,
1128
]
],
[
[
272,
24,
537
],
[
537... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u} (Com... | Chlorpheniramine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Flavoxate (Compound)
Chlorpheniramine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Flavoxate (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases w... |
DB00731 | DB01232 | 1,144 | 1,327 | [
"DDInter1269",
"DDInter1640"
] | Nateglinide | Saquinavir | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
1144,
24,
1327
]
],
[
[
1144,
63,
798
],
[
798,
40,
1327
]
],
[
[
1144,
24,
915
],
[
915,
40,
1327
]
],
[
[
1144,
1,
11425
],
[
11425,... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound... |
DB00500 | DB01097 | 24 | 1,377 | [
"DDInter1831",
"DDInter1033"
] | Tolmetin | Leflunomide | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
24,
25,
1377
]
],
[
[
24,
10,
11577
],
[
11577,
44,
1377
]
],
[
[
24,
21,
28864
],
[
28864,
60,
1377
]
],
[
[
24,
25,
126
],
[
126,
... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Tolmetin",
"{u} (Compound) palliates {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) is treat... | Tolmetin (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Leflunomide (Compound)
Tolmetin (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Leflunomide (Compound)
Tolmetin may lead to a major life threatening intera... |
DB00342 | DB08827 | 1,181 | 990 | [
"DDInter1770",
"DDInter1085"
] | Terfenadine | Lomitapide | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1181,
24,
990
]
],
[
[
1181,
25,
1080
],
[
1080,
1,
990
]
],
[
[
1181,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1181,
24,
77
],
[
77,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivapt... | Terfenadine may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate disea... |
DB00924 | DB12010 | 1,405 | 214 | [
"DDInter454",
"DDInter785"
] | Cyclobenzaprine | Fostamatinib | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1405,
24,
214
]
],
[
[
1405,
63,
723
],
[
723,
24,
214
]
],
[
[
1405,
24,
1362
],
[
1362,
24,
214
]
],
[
[
1405,
24,
1017
],
[
1017,
... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
... | Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib ... |
DB00819 | DB01362 | 471 | 497 | [
"DDInter15",
"DDInter960"
] | Acetazolamide | Iohexol | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
471,
24,
497
]
],
[
[
471,
24,
258
],
[
258,
40,
497
]
],
[
[
471,
21,
29750
],
[
29750,
60,
497
]
],
[
[
471,
1,
997
],
[
997,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Acetazolamide (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Iohexol (Compound)
Acetazolamide (Compound) r... |
DB01607 | DB09268 | 1,390 | 1,662 | [
"DDInter1803",
"DDInter1464"
] | Ticarcillin | Picosulfuric acid | An antibiotic derived from penicillin similar to carbenicillin in action. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1390,
24,
1662
]
],
[
[
1390,
63,
597
],
[
597,
24,
1662
]
],
[
[
1390,
1,
319
],
[
319,
24,
1662
]
],
[
[
1390,
40,
916
],
[
916,
... | [
[
[
"Ticarcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ticarcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Ticarcillin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ticarcillin (Compound) resembles Amoxicillin (Compound) and Amoxicillin may cause a moderate i... |
DB00500 | DB11703 | 24 | 405 | [
"DDInter1831",
"DDInter9"
] | Tolmetin | Acalabrutinib | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
24,
25,
405
]
],
[
[
24,
23,
1194
],
[
1194,
24,
405
]
],
[
[
24,
24,
121
],
[
121,
24,
405
]
],
[
[
24,
24,
738
],
[
738,
63,
... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Tolmetin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
... | Tolmetin may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenflur... |
DB00808 | DB06203 | 1,605 | 1,002 | [
"DDInter916",
"DDInter51"
] | Indapamide | Alogliptin | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1605,
24,
1002
]
],
[
[
1605,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1605,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
1605,
21,
28873
],
[
28... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Indapamide (Compound) causes Pancreatitis (Side Effect) and Panc... |
DB00998 | DB01191 | 404 | 1,039 | [
"DDInter788",
"DDInter518"
] | Frovatriptan | Dexfenfluramine | Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
404,
25,
1039
]
],
[
[
404,
6,
7950
],
[
7950,
45,
1039
]
],
[
[
404,
24,
868
],
[
868,
63,
1039
]
],
[
[
404,
63,
475
],
[
475,
... | [
[
[
"Frovatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Frovatriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Frovatriptan (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound)
Frovatriptan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Fr... |
DB08826 | DB08865 | 1,292 | 1,593 | [
"DDInter489",
"DDInter448"
] | Deferiprone | Crizotinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1292,
25,
1593
]
],
[
[
1292,
18,
2215
],
[
2215,
57,
1593
]
],
[
[
1292,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
1292,
25,
283
],
[
2... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Deferiprone",
"{u} (Compound) downregulates {v} (Gene)",
"HSPA8"
],
[
"HSPA8",
"{u} (Gene) is downregulated by {v} (Compound)"... | Deferiprone (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Crizotinib (Compound)
Deferiprone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Deferiprone may lead to a major life threatening interaction when taken with Fedratinib and Fedrat... |
DB00224 | DB09074 | 215 | 1,362 | [
"DDInter917",
"DDInter1327"
] | Indinavir | Olaparib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
215,
25,
1362
]
],
[
[
215,
24,
2
],
[
2,
24,
1362
]
],
[
[
215,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
215,
63,
168
],
[
168,
24... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
],
[
"Alosetron",
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Indinavir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a modera... |
DB00637 | DB13139 | 1,557 | 1,032 | [
"DDInter128",
"DDInter1063"
] | Astemizole | Levosalbutamol | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1557,
24,
1032
]
],
[
[
1557,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1557,
24,
124
],
[
124,
24,
1032
]
],
[
[
1557,
25,
982
],
[
982,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabo... | Astemizole may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may ... |
DB00014 | DB00889 | 521 | 1,133 | [
"DDInter839",
"DDInter840"
] | Goserelin | Granisetron | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
521,
24,
1133
]
],
[
[
521,
21,
29282
],
[
29282,
60,
1133
]
],
[
[
521,
23,
112
],
[
112,
62,
1133
]
],
[
[
521,
24,
1213
],
[
1213,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is cau... | Goserelin (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granisetron (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gran... |
DB00515 | DB01284 | 589 | 1,042 | [
"DDInter387",
"DDInter1782"
] | Cisplatin | Tetracosactide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
589,
24,
1042
]
],
[
[
589,
24,
1683
],
[
1683,
63,
1042
]
],
[
[
589,
25,
1137
],
[
1137,
63,
1042
]
],
[
[
589,
24,
1664
],
[
1664,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cisplatin may lead to a major life threatening interaction when taken with Measles virus vaccine live atten... |
DB00443 | DB01278 | 251 | 1,021 | [
"DDInter195",
"DDInter1506"
] | Betamethasone | Pramlintide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
251,
24,
1021
]
],
[
[
251,
40,
1103
],
[
1103,
23,
1021
]
],
[
[
251,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
251,
24,
1680
],
[
1680,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction t... |
DB00603 | DB14723 | 303 | 159 | [
"DDInter1137",
"DDInter1026"
] | Medroxyprogesterone acetate | Larotrectinib | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
303,
24,
159
]
],
[
[
303,
24,
1375
],
[
1375,
24,
159
]
],
[
[
303,
24,
1412
],
[
1412,
63,
159
]
],
[
[
303,
40,
1486
],
[
1486,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases wh... |
DB00486 | DB00524 | 1,614 | 811 | [
"DDInter1253",
"DDInter1199"
] | Nabilone | Metolazone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
1614,
24,
811
]
],
[
[
1614,
24,
1605
],
[
1605,
40,
811
]
],
[
[
1614,
24,
1014
],
[
1014,
1,
811
]
],
[
[
1614,
21,
28850
],
[
28850... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Metolazone (Compound)
... |
DB00280 | DB01409 | 494 | 1,415 | [
"DDInter575",
"DDInter1815"
] | Disopyramide | Tiotropium | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
494,
24,
1415
]
],
[
[
494,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
494,
21,
28680
],
[
28680,
60,
1415
]
],
[
[
494,
23,
752
],
[
752,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)... | Disopyramide (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Disopyramide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Tiotropium (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine m... |
DB00787 | DB01032 | 387 | 824 | [
"DDInter25",
"DDInter1522"
] | Acyclovir | Probenecid | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Minor | 0 | [
[
[
387,
23,
824
]
],
[
[
387,
6,
16560
],
[
16560,
45,
824
]
],
[
[
387,
7,
5780
],
[
5780,
57,
824
]
],
[
[
387,
21,
28722
],
[
28722,
... | [
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Probenecid"
]
],
[
[
"Acyclovir",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
... | Acyclovir (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Probenecid (Compound)
Acyclovir (Compound) upregulates ARNT2 (Gene) and ARNT2 (Gene) is downregulated by Probenecid (Compound)
Acyclovir (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Probenecid (Compound)
Acyclovir m... |
DB00191 | DB00777 | 73 | 146 | [
"DDInter1447",
"DDInter1537"
] | Phentermine | Propiomazine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
73,
24,
146
]
],
[
[
73,
24,
508
],
[
508,
1,
146
]
],
[
[
73,
24,
401
],
[
401,
63,
146
]
],
[
[
73,
24,
104
],
[
104,
40,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that... |
DB00363 | DB00414 | 695 | 590 | [
"DDInter419",
"DDInter16"
] | Clozapine | Acetohexamide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
695,
24,
590
]
],
[
[
695,
24,
660
],
[
660,
62,
590
]
],
[
[
695,
64,
168
],
[
168,
24,
590
]
],
[
[
695,
24,
874
],
[
874,
63,... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Clozapine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cau... |
DB00694 | DB12035 | 51 | 943 | [
"DDInter485",
"DDInter1641"
] | Daunorubicin | Sarecycline | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
51,
24,
943
]
],
[
[
51,
63,
1181
],
[
1181,
24,
943
]
],
[
[
51,
24,
1670
],
[
1670,
24,
943
]
],
[
[
51,
35,
77
],
[
77,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and... |
DB09075 | DB13879 | 498 | 1,043 | [
"DDInter621",
"DDInter824"
] | Edoxaban | Glecaprevir | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Major | 2 | [
[
[
498,
25,
1043
]
],
[
[
498,
25,
971
],
[
971,
24,
1043
]
],
[
[
498,
64,
868
],
[
868,
24,
1043
]
],
[
[
498,
24,
1017
],
[
1017,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glecaprevir"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} ... | Edoxaban may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Edoxaban may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate i... |
DB00762 | DB06674 | 613 | 908 | [
"DDInter973",
"DDInter837"
] | Irinotecan | Golimumab | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
613,
25,
908
]
],
[
[
613,
63,
1461
],
[
1461,
23,
908
]
],
[
[
613,
24,
336
],
[
336,
24,
908
]
],
[
[
613,
25,
697
],
[
697,
2... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine ... |
DB00214 | DB00798 | 1,028 | 1,132 | [
"DDInter1836",
"DDInter815"
] | Torasemide | Gentamicin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Major | 2 | [
[
[
1028,
25,
1132
]
],
[
[
1028,
18,
2976
],
[
2976,
57,
1132
]
],
[
[
1028,
21,
28762
],
[
28762,
60,
1132
]
],
[
[
1028,
25,
361
],
[
3... | [
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
]
],
[
[
"Torasemide",
"{u} (Compound) downregulates {v} (Gene)",
"STUB1"
],
[
"STUB1",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Torasemide (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Gentamicin (Compound)
Torasemide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Gentamicin (Compound)
Torasemide may lead to a major life threatening interaction when taken with Neomycin and Neomycin ... |
DB01242 | DB04868 | 1,237 | 478 | [
"DDInter410",
"DDInter1293"
] | Clomipramine | Nilotinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
1237,
25,
478
]
],
[
[
1237,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1237,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1237,
21,
28963
],
[
28963... | [
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatini... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Clomipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Clomipramine (Compou... |
DB09073 | DB14840 | 951 | 861 | [
"DDInter1379",
"DDInter1601"
] | Palbociclib | Ripretinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
951,
24,
861
]
],
[
[
951,
24,
351
],
[
351,
24,
861
]
],
[
[
951,
63,
353
],
[
353,
24,
861
]
],
[
[
951,
64,
384
],
[
384,
25,... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Gr... |
DB09389 | DB11827 | 517 | 433 | [
"DDInter1315",
"DDInter669"
] | Norgestrel | Ertugliflozin | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
517,
24,
433
]
],
[
[
517,
63,
959
],
[
959,
24,
433
]
],
[
[
517,
25,
1476
],
[
1476,
63,
433
]
],
[
[
517,
24,
1296
],
[
1296,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Norgestrel may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause... |
DB01174 | DB06605 | 697 | 1,409 | [
"DDInter1442",
"DDInter108"
] | Phenobarbital | Apixaban | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
697,
25,
1409
]
],
[
[
697,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
697,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
697,
25,
1670
],
[
1670,... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Api... | Phenobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Phenobarbital (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Phenobarbital may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat m... |
DB00563 | DB01259 | 663 | 392 | [
"DDInter1174",
"DDInter1024"
] | Methotrexate | Lapatinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
663,
24,
392
]
],
[
[
663,
5,
11579
],
[
11579,
44,
392
]
],
[
[
663,
6,
4973
],
[
4973,
45,
392
]
],
[
[
663,
7,
10248
],
[
10248,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is t... | Methotrexate (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Methotrexate (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Lapatinib (Compound)
Me... |
DB00204 | DB09065 | 228 | 760 | [
"DDInter580",
"DDInter424"
] | Dofetilide | Cobicistat | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
228,
24,
760
]
],
[
[
228,
23,
1101
],
[
1101,
23,
760
]
],
[
[
228,
25,
1374
],
[
1374,
23,
760
]
],
[
[
228,
24,
723
],
[
723,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Dofetilide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a ... |
DB08865 | DB09080 | 1,593 | 144 | [
"DDInter448",
"DDInter1331"
] | Crizotinib | Olodaterol | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1593,
24,
144
]
],
[
[
1593,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1593,
64,
956
],
[
956,
24,
144
]
],
[
[
1593,
25,
1011
],
[
1011,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Crizotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Crizotinib may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin ... |
DB00026 | DB04845 | 1,184 | 309 | [
"DDInter94",
"DDInter1001"
] | Anakinra | Ixabepilone | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1184,
24,
309
]
],
[
[
1184,
24,
60
],
[
60,
23,
309
]
],
[
[
1184,
24,
1419
],
[
1419,
24,
309
]
],
[
[
1184,
24,
1619
],
[
1619,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib ... |
DB00019 | DB06810 | 1,257 | 397 | [
"DDInter1405",
"DDInter1484"
] | Pegfilgrastim | Plicamycin | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
1257,
24,
397
]
],
[
[
1257,
24,
384
],
[
384,
63,
397
]
],
[
[
1257,
24,
869
],
[
869,
24,
397
]
],
[
[
1257,
24,
1172
],
[
1172,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and T... |
DB00673 | DB04575 | 723 | 35 | [
"DDInter112",
"DDInter1555"
] | Aprepitant | Quinestrol | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
723,
24,
35
]
],
[
[
723,
63,
566
],
[
566,
1,
35
]
],
[
[
723,
24,
1197
],
[
1197,
1,
35
]
],
[
[
723,
63,
1336
],
[
1336,
40,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Quinestrol (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Quines... |
DB01162 | DB11130 | 195 | 407 | [
"DDInter1767",
"DDInter1344"
] | Terazosin | Opium | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
195,
24,
407
]
],
[
[
195,
1,
1433
],
[
1433,
24,
407
]
],
[
[
195,
63,
104
],
[
104,
24,
407
]
],
[
[
195,
24,
849
],
[
849,
24... | [
[
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
],
[
"Doxazosin",
"{u} may cause a moderate interac... | Terazosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exac... |
DB00092 | DB01234 | 58 | 1,220 | [
"DDInter40",
"DDInter513"
] | Alefacept | Dexamethasone | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
58,
24,
1220
]
],
[
[
58,
24,
870
],
[
870,
1,
1220
]
],
[
[
58,
24,
175
],
[
175,
40,
1220
]
],
[
[
58,
24,
1382
],
[
1382,
23,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00911 | DB08889 | 458 | 350 | [
"DDInter1811",
"DDInter299"
] | Tinidazole | Carfilzomib | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
458,
24,
350
]
],
[
[
458,
21,
28762
],
[
28762,
60,
350
]
],
[
[
458,
24,
1060
],
[
1060,
63,
350
]
],
[
[
458,
24,
310
],
[
310,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Tinidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Tinidazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when tak... |
DB01041 | DB09228 | 770 | 687 | [
"DDInter1789",
"DDInter437"
] | Thalidomide | Conestat alfa | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibi... | Major | 2 | [
[
[
770,
25,
687
]
],
[
[
770,
64,
11
],
[
11,
24,
687
]
],
[
[
770,
25,
890
],
[
890,
24,
687
]
],
[
[
770,
25,
192
],
[
192,
63,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conestat alfa"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"... | Thalidomide may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Thalidomide may lead to a major life threatening interaction when taken with Mestranol and Mestranol may cause a moderate i... |
DB00563 | DB08895 | 663 | 976 | [
"DDInter1174",
"DDInter1825"
] | Methotrexate | Tofacitinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
663,
25,
976
]
],
[
[
663,
63,
1461
],
[
1461,
23,
976
]
],
[
[
663,
25,
660
],
[
660,
24,
976
]
],
[
[
663,
24,
214
],
[
214,
6... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Methotrexate may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole may c... |
DB00262 | DB00515 | 552 | 589 | [
"DDInter302",
"DDInter387"
] | Carmustine | Cisplatin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
552,
24,
589
]
],
[
[
552,
5,
11555
],
[
11555,
44,
589
]
],
[
[
552,
21,
29118
],
[
29118,
60,
589
]
],
[
[
552,
23,
956
],
[
956,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Carmustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cisplatin (Compound)
Carmustine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Cisplatin (Compound)
Carmustine may cause a minor interaction that can limit clinical effects wh... |
DB00501 | DB01066 | 752 | 1,462 | [
"DDInter380",
"DDInter316"
] | Cimetidine | Cefditoren | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
752,
24,
1462
]
],
[
[
752,
24,
665
],
[
665,
40,
1462
]
],
[
[
752,
23,
115
],
[
115,
63,
1462
]
],
[
[
752,
24,
126
],
[
126,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interact... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.